Trial Profile
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Olaparib (Primary) ; Vistusertib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 15 Feb 2024 Planned End Date changed from 20 Jun 2024 to 20 Dec 2024.
- 15 Feb 2024 Planned primary completion date changed from 20 Jun 2024 to 20 Dec 2024.
- 20 Jul 2023 Planned End Date changed from 30 Jun 2023 to 20 Jun 2024.